

119TH CONGRESS
2D SESSION

H. R. 7879

To require the Secretary of State, in consultation with the Secretary of Health and Human Services and other relevant departments and agencies, as appropriate, to formulate a strategy for the Federal Government to secure support from foreign countries, multilateral organizations, and other appropriate entities to facilitate the development and commercialization of qualified pandemic or epidemic products, and for other purposes.

IN THE HOUSE OF REPRESENTATIVES

MARCH 9, 2026

Mr. LEVIN (for himself and Mr. VALADAO) introduced the following bill; which was referred to the Committee on Foreign Affairs

A BILL

To require the Secretary of State, in consultation with the Secretary of Health and Human Services and other relevant departments and agencies, as appropriate, to formulate a strategy for the Federal Government to secure support from foreign countries, multilateral organizations, and other appropriate entities to facilitate the development and commercialization of qualified pandemic or epidemic products, and for other purposes.

1 *Be it enacted by the Senate and House of Representa-*
2 *tives of the United States of America in Congress assembled,*

1 **SECTION 1. SHORT TITLES.**

2 This Act may be cited as the “Saving Us from Pan-
3 demic Era Resistance by Building a Unified Global Strat-
4 egy Act of 2026” or the “SUPER BUGS Act of 2026”.

5 **SEC. 2. FINDINGS.**

6 Congress finds the following:

7 (1) Emerging infectious diseases, including
8 antimicrobial-resistant pathogens, pose a significant
9 threat to United States national security by—

10 (A) increasing the risk of outbreaks reach-
11 ing the United States;

12 (B) disrupting critical infrastructure;

13 (C) undermining economic stability and
14 public health; and

15 (D) undermining the readiness of the
16 United States Armed Forces abroad.

17 (2) Strengthening international collaboration to
18 develop, commercialize, and deploy qualified pan-
19 demic and epidemic products is essential to pre-
20 venting, detecting, and containing infectious disease
21 threats before they reach the borders of the United
22 States.

23 (3) Enhancing partner countries’ public health
24 capabilities and pandemic and epidemic response
25 mechanisms directly contributes to United States

1 homeland security by reducing the likelihood of glob-
2 al outbreaks affecting the United States.

3 (4) Coordinated strategies that leverage United
4 States leadership, technology, and medical counter-
5 measures, while ensuring equitable access for inter-
6 national partners, promote global resilience and re-
7 duce threats to United States citizens, infrastruc-
8 ture, and national interests.

9 **SEC. 3. DEFINITIONS.**

10 In this Act:

11 (1) APPROPRIATE COMMITTEES OF CON-
12 GRESS.—The term “appropriate committees of Con-
13 gress” means—

14 (A) the Committee on Foreign Relations of
15 the Senate;

16 (B) the Committee on Health, Education,
17 Labor, and Pensions of the Senate;

18 (C) the Committee on Foreign Affairs of
19 the House of Representatives; and

20 (D) the Committee on Energy and Com-
21 merce of the House of Representatives.

22 (2) PRIORITY PATHOGENS.—The term “priority
23 pathogens” means pathogens identified in—

24 (A) the latest “Antibiotic Resistance
25 Threats Report” of the Centers for Disease

1 Control and Prevention (or any successor re-
 2 port); or

3 (B) the current list of qualifying pathogens
 4 maintained by the Secretary of Health and
 5 Human Services under section 505E(f)(2) of
 6 the Federal Food, Drug, and Cosmetic Act (21
 7 U.S.C. 355f(f)(2)) (or any successor list).

8 (3) QUALIFIED PANDEMIC OR EPIDEMIC PROD-
 9 UCT.—The term “qualified pandemic or epidemic
 10 product” has the meaning given such term in section
 11 319F–3(i) of the Public Health Service Act (42
 12 U.S.C. 247d–6d(i)).

13 **SEC. 4. INTERNATIONAL STRATEGY FOR DEVELOPMENT OF**
 14 **QUALIFIED PANDEMIC OR EPIDEMIC PROD-**
 15 **UCTS.**

16 (a) STRATEGY.—

17 (1) IN GENERAL.—Not later than 18 months
 18 after the date of the enactment of this Act, the Sec-
 19 retary of State, in consultation with the Secretary of
 20 Health and Human Services, and such other heads
 21 of departments and agencies as the Secretary of
 22 State considers appropriate, shall—

23 (A) formulate a strategy for the Federal
 24 Government to secure support from foreign
 25 countries, multilateral organizations, and other

1 appropriate entities to facilitate the develop-
2 ment and commercialization of qualified pan-
3 demic or epidemic products, including products
4 to address antimicrobial resistant pathogens—

5 (i) with pandemic potential; or

6 (ii) that are priority pathogens; and

7 (B) submit such strategy to the appro-
8 priate committees of Congress.

9 (2) CONTENTS.—The strategy required under
10 paragraph (1) shall—

11 (A) provide for processes the Federal Gov-
12 ernment is using and would use to enter into
13 arrangements with foreign countries, multilat-
14 eral organizations, and other appropriate enti-
15 ties in certain circumstances to implement the
16 strategy;

17 (B) strive to ensure that the arrangements
18 described in subparagraph (A) promote equi-
19 table contributions based on the budgets and
20 technical expertise of participating countries,
21 organizations, and other entities, as appro-
22 priate;

23 (C) focus the arrangements described in
24 subparagraph (A) on global priorities, while en-
25 abling participating countries, organizations,

1 and other entities to emphasize national or re-
2 gional issues of importance;

3 (D) support efforts to strengthen partner
4 country public health capabilities by promoting
5 sustainable improvements in their ability to pre-
6 vent, detect, and contain infectious disease
7 threats;

8 (E) seek to ensure that new and existing
9 arrangements described in subparagraph (A)
10 are harmonized with each other and with other
11 relevant existing or planned efforts to amplify
12 impact, address gaps, prevent duplication of ef-
13 fort, and efficiently distribute funds;

14 (F) provide for collaboration to ensure the
15 arrangements described in subparagraph (A) al-
16 locate joint or individual responsibility across
17 participating countries, organizations, and other
18 entities for the development and commercializa-
19 tion of particular qualified pandemic or epi-
20 demic products, where such collaboration is
21 clearly described in such arrangement;

22 (G) provide for the stewardship of qualified
23 pandemic or epidemic products developed pur-
24 suant to the strategy;

1 (H) identify priority actions in the ar-
2 rangements described in subparagraph (A) so
3 that scarce domestic and international funds
4 are allocated to develop and commercialize
5 qualified pandemic or epidemic products that
6 can achieve the greatest positive impact on
7 human health, including unprecedented ap-
8 proaches to preventing, treating, and diag-
9 nosing infectious diseases;

10 (I) consider securing contracts with United
11 States companies and the broader private sec-
12 tor, entering into public-private partnerships,
13 implementing alternative payment models, cre-
14 ating coverage and reimbursement pathways,
15 and streamlining regulatory approval processes;
16 and

17 (J) be synchronized with United States
18 pandemic preparedness priorities, such as those
19 articulated in—

20 (i) the National Strategy for Com-
21 bating Antibiotic-Resistant Bacteria (dated
22 September 2014); and

23 (ii) the National Biodefense Strategy
24 and Implementation Plan (dated October

1 2022) and the associated Action Plan
2 (dated October 2022).

3 (b) ARRANGEMENTS WITH FOREIGN COUNTRIES
4 AND MULTILATERAL ORGANIZATIONS.—The Secretary of
5 State, in consultation with the Secretary of Health and
6 Human Services, and the heads of other relevant depart-
7 ments and agencies, as appropriate, shall seek to enter
8 into arrangements with foreign countries, multilateral or-
9 ganizations, and other appropriate entities to implement
10 the strategy required under subsection (a).

○